Literature DB >> 15101716

Flow cytometric analysis of the expression of Fas/Fasl in bone marrow CD34+ cells in myelodysplastic syndromes: relation to disease progression.

Elisangela Ribeiro1, Carmen S P Lima, Konradin Metze, Irene Lorand-Metze.   

Abstract

The role of apoptosis in the pathobiology of myelodysplastic syndromes (MDS) remains controversial. We studied the expression of CD95 and CD95L in CD34+ cells of patients with newly diagnosed MDS by flow cytometry, and examined the relation between this expression and FAB and WHO types, total number of CD34+ bone marrow (BM) cells and the degree of peripheral cytopenias. The patients with refractory anemia (RA) and sideroblastic anemia showed CD34+ cells in numbers comparable to normal donors, but had a higher percentage of CD95/CD34 and CD95L/CD34 positive cells. An inverse correlation was found between these cells and the total CD34+ cells. This was also observed when only patients with RA were analyzed. In RAEB, however, CD95/CD95L expression correlated with CD34+ cells but not with the percentage of BM blasts. After classification by the WHO proposal, the patients with refractory cytopenias with multilineage dysplasia showed features intermediary between RA and RAEB. No significant correlation was seen between the expression of CD95/CD95L and the peripheral blood counts. These results are in keeping with the hypothesis that, as the number of MDS precursors increases during disease progression they become less succeptible to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15101716     DOI: 10.1080/10428190310001598044

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Authors:  Kathryn S Ivy; P Brent Ferrell
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

2.  Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes.

Authors:  Joyce R Vido; Randall L Adam; Irene G H Lorand-Metze; Konradin Metze
Journal:  Diagn Pathol       Date:  2011-09-29       Impact factor: 2.644

3.  Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.

Authors:  Suiellen C Reis-Alves; Fabiola Traina; Konradin Metze; Irene Lorand-Metze
Journal:  Diagn Pathol       Date:  2015-04-29       Impact factor: 2.644

4.  Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.

Authors:  Suiellen C Reis-Alves; Fabíola Traina; Guilherme Harada; Paula M Campos; Sara T O Saad; Konradin Metze; Irene Lorand-Metze
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.